Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study

Autor: Edouard Louis, Frank Hoentjen, Mette Julsgaard, Annelies Posen, Wouter Van Moerkercke, Cyrielle Gilletta De Saint-Joseph, A Cremer, Juliette Sheridan, Severine Vermeire, Daniel C. Baumgart, Anneleen Van Hootegem, Evelien Humblet, Zoran Milenkovic, Thomas Krause, Jochen Nijs, C. Janneke van der Woude, Elisabeth Macken, Peter Bossuyt, Carl Eriksson, Marc Ferrante, Jean-François Rahier, Annick Moens, Sophie Dewit, Stéphane Nancey, Ariella Bar-Gil Shitrit

Publikováno v: Alimentary Pharmacology & Therapeutics, 51, 1, pp. 129-138
Alimentary pharmacology & therapeutics, Vol. 51, no. 1, p. 129-138 (2020)
Alimentary pharmacology & therapeutics, 51 (1
Alimentary pharmacology and therapeutics
Alimentary Pharmacology & Therapeutics, 51, 129-138
Moens, A, van der Woude, C J, Julsgaard, M, Humblet, E, Sheridan, J, Baumgart, D C, Gilletta De Saint-Joseph, C, Nancey, S, Rahier, J-F, Bossuyt, P, Cremer, A, Dewit, S, Eriksson, C, Hoentjen, F, Krause, T, Louis, E, Macken, E, Milenkovic, Z, Nijs, J, Posen, A, Van Hootegem, A, Van Moerkercke, W, Vermeire, S, Bar-Gil Shitrit, A & Ferrante, M 2020, ' Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy : results of the European CONCEIVE study ', Alimentary Pharmacology and Therapeutics, vol. 51, no. 1, pp. 129-138 . https://doi.org/10.1111/apt.15539

Women with inflammatory bowel diseases (IBD) often receive biologicals during pregnancy to maintain disease remission. Data on outcome of vedolizumab-exposed pregnancies (VDZE) are sparse.
info:eu-repo/semantics/published

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ecd0319fb2a7973387a49d4be2a8ae9
https://hdl.handle.net/2066/220130

Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab

Autor: Elisabeth Macken, Wouter Van Moerkercke, Evelien Humblet, Sophie Dewit, Beatrijs Strubbe, Marc Ferrante, Karen van Hoeve, Jean-François Rahier, Annick Moens, Denis Franchimont, Annelies Posen, Peter Bossuyt, Jochen Nijs, Severine Vermeire, Anneleen Van Hootegem

Publikováno v: Journal of Crohn's and colitis

Background and Aims: Vedolizumab is an IgG1 anti-alpha 4 beta 7 integrin antibody approved for the treatment of inflammatory bowel diseases[IBD], but without clear safety data during conception, pregnancy and nursing. Animal studies showed that mucos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::218a06552a947b2d9eccaf1b8b1f5335
https://pubmed.ncbi.nlm.nih.gov/30281093

OP032 Outcome of pregnancies in female IBD patients treated with vedolizumab

Autor: Annick Moens, Marc Ferrante, Denis Franchimont, Annelies Posen, A. Van Hootegem, Jochen Nijs, J F Rahier, Evelien Humblet, W Van Moerkercke, K van Hoeve, P Bossuyt, Sophie Dewit, Elisabeth Macken, Severine Vermeire

Publikováno v: Journal of Crohn's and Colitis. 12:S022-S023

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::834a7647a99e605657ab970fc79ab2e9
https://doi.org/10.1093/ecco-jcc/jjx180.031

Sa1697 - Outcome of Pregnancies in Vedolizumab Treated Female IBD Patients

Autor: Jean-François Rahier, Annick Moens, Evelien Humblet, Marc Ferrante, Annelies Posen, Peter Bossuyt, Macken Elisabeth, Anneleen Van Hootegem, Sophie Dewit, Karen van Hoeve, Severine Vermeire, Jochen Nijs, Denis Franchimont, Wouter Van Moerkercke

Publikováno v: Gastroenterology. 154:S-360

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::030f20bde1eb3ec65c17025901b50483
https://doi.org/10.1016/s0016-5085(18)31521-x